前列腺切除术后挽救放疗:不同分割方案的早期不良事件与患者报告结局
URONCOR 06-24 III期试验预设中期分析纳入前250例前列腺切除术后挽救放疗患者,比较中度大分割(175例)与常规分割(75例)的早期不良事件和患者报告结局。中位随访12.7个月,两组≥2级泌尿生殖和胃肠道不良事件无显著差异,患者报告结局无临床意义差异。
要点
- 中度大分割组≥2级泌尿生殖不良事件21.7%,常规分割组17.3%,差异无统计学意义。
- 中度大分割组≥2级胃肠道不良事件10.8%,常规分割组4.0%,差异无统计学意义。
- 盆腔淋巴结照射在大分割组更常见,且与≥2级胃肠道不良事件风险增加相关。
核心结论
- 前列腺切除术后挽救放疗的早期不良事件发生率低,两种分割方案相当。
- 中度大分割在更频繁盆腔照射情况下仍显示相似安全性。
- 因分割方案非随机,需更长随访和偏倚调整后才能定论比较安全性。
研究设计与样本
- URONCOR 06-24前瞻性多中心III期随机试验的预设中期分析。
- 纳入首批250例前列腺切除术后挽救放疗患者,中度大分割175例,常规分割75例。
- 不良事件用CTCAE v5.0评估,患者报告结局用EPIC-26和EORTC QLQ-C30在基线、3和6个月评估。
主要发现
- 中位随访12.7个月,≥2级泌尿生殖不良事件在大分割组21.7% vs 常规分割组17.3%(p=0.431)。
- ≥2级胃肠道不良事件在大分割组10.8% vs 常规分割组4.0%(p=0.079)。
- 盆腔淋巴结照射在大分割组39.4% vs 常规分割组13.3%(p=0.001)。
- 多变量分析中,年龄与≥2级泌尿生殖不良事件风险增加相关,盆腔淋巴结照射与≥2级胃肠道不良事件风险增加相关。
- 患者报告结局未见有临床意义的差异。
关键数值与推荐
- 中度大分割最常见方案为62.5 Gy分25次(80.5%),其余为65.25 Gy分29次(7.5%)、60 Gy分24次(4.6%)、52.5 Gy分20次(2.9%)。
- 中度大分割对应生物等效剂量(EQ.D2,α/β=1.5)约65-71 Gy。
- 常规分割为66-70 Gy分33-35次。
临床怎么用
- 前列腺切除术后挽救放疗可考虑中度大分割,早期不良事件与常规分割相当。
- 盆腔淋巴结照射患者需关注胃肠道不良事件风险。
- 年龄较大患者需关注泌尿生殖不良事件风险。
局限性
- 分割方案非随机分配,存在治疗选择偏倚。
- 随访时间较短(中位12.7个月),仅报告早期不良事件。
- 需更长随访和稳健的偏倚调整后才能得出比较安全性的确切结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Moderate hypofractionation is increasingly used in salvage radiotherapy (SRT) after radical prostatectomy, although prospective data in the postoperative setting remain limited. We evaluated early adverse events and patient-reported outcomes (PROs) according to fractionation schedule within a prospective multicenter phase III trial. MATERIALS AND METHODS: This prespecified interim analysis included the first 250 patients enrolled in the URONCOR 06-24 randomized trial (NCT05781217). SRT was delivered using moderate hypofractionation (n = 175), most commonly 62.5 Gy in 25 fractions (80.5%), followed by 65.25 Gy in 29 fractions (7.5%), 60 Gy in 24 fractions (4.6%), and 52.5 Gy in 20 fractions (2.9%), corresponding to a biologically equivalent dose (EQ.D2) of approximately 65-71 Gy (α/β = 1.5), or conventional fractionation (n = 75; 66-70 Gy in 33-35 fractions). Adverse events were assessed using CTCAE v5.0. PROs were evaluated using EPIC-26 and EORTC QLQ-C30 at baseline, 3, and 6 months. RESULTS: With a median follow-up of 12.7 months, grade ≥ 2 genitourinary (GU) adverse events occurred in 21.7% of patients treated with hypofractionation versus 17.3% with conventional fractionation (p = 0.431). Grade ≥ 2 gastrointestinal (GI) adverse events occurred in 10.8% and 4.0%, respectively (p = 0.079). Pelvic nodal irradiation was more frequent in the hypofractionation group (39.4% vs 13.3%, p = 0.001). On multivariable analysis, age was associated with increased risk of GU ≥2 adverse events, while pelvic nodal irradiation was associated with increased risk of GI ≥2 adverse events. No clinically meaningful differences were observed in PROs. CONCLUSION: Early adverse events after SRT were low and comparable between fractionation schedules, and moderate hypofractionation showed a similar safety profile despite more frequent pelvic irradiation. However, given the non-randomized nature of the fractionation schedules, longer follow-up and robust adjustment for treatment-selection biases are needed before drawing definitive conclusions regarding comparative safety.
引用
- Couñago F, González C, Gómez-Iturriaga A, et al. Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial. Clin Transl Radiat Oncol. 2026. PMID: 42741462. doi:10.1016/j.ctro.2026.101276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。